Last reviewed · How we verify

NCT06955572: METARICH

Descriptive Study of the Gene Count in Faecal Microbiota

Completed Last updated 2 May 2025
What this trial tests

trial testing Patients with colorectal cancer in Microbiota in 400 participants. Completed in 22 July 2024.

Timeline
28 February 2023
Primary endpoint
22 May 2024
22 July 2024

Quick facts

Lead sponsorUniversity Hospital, Rouen
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date28 February 2023
Primary completion22 May 2024
Estimated completion22 July 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 75, any sex, with Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis of METARICH Study is that it is possible to draw up a profile of the faecal microbiota, which could contribute in the future to the characterisation of certain chronic pathologies. The pathologies chosen for the study were selected because they are associated in the literature with changes in the faecal microbiota.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Microbiota

Currently open trials in the same condition.

Other University Hospital, Rouen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06955572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing